Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
PALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to December 31, 2022.
- PALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (Agreement) regarding Acuras LIMITx LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (AD Pharma) to extend the FDA Acceptance Date for LTX-03 (NDA Acceptance Date) to December 31, 2022.
- The Company expects to complete clinical studies and other required steps to file the NDA and gain regulatory acceptance by that date.
- Suicide is increasingly seen as the only remedy for some of these patients through opioid overdose.
- LIMITx is useful with products whose side effect risks can be mitigated by limiting exposure to a drug in overdose situations.